---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-178947"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:24:26.049145+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q2 2025 cash $248.9M; 12% workforce cut; FT819 lupus response durable

## Summary
- Q2 2025 cash, cash equivalents & investments $248.9M; total revenue $1.9M from Ono collaboration; operating expenses $38.9M.
- Board approved 12% workforce reduction; expects severance charges of $0.9M–$1.2M in Q3 2025; cash runway extended through YE 2027.
- FT819 SLE/LN: First patient on fludarabine-free conditioning achieved DORIS at 12-month follow-up; first extrarenal SLE patient without conditioning achieved LLDAS at 3 & 6 months.
- FDA allowed IND for FT836 MICA/B-targeted CAR T-cell program; Phase 1 to test without conditioning chemotherapy in solid tumors.
- Ono collaboration extended for second solid tumor CAR T candidate through at least June 2026.

## SEC filing metadata
- accession: 0001193125-25-178947
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312525178947/0001193125-25-178947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312525178947/d452012d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-178947
- JSON: https://secwatch.observer/filing/0001193125-25-178947.json
- Plain text: https://secwatch.observer/filing/0001193125-25-178947.txt

## Key facts
- Restructurings & Charges
  FATE THERAPEUTICS INC announced a restructuring with charges of approximately $0.9 million to $1.2 million (approximately 12%).
  - Type: restructuring
  - Charge: approximately $0.9 million to $1.2 million
  - Headcount: approximately 12%
  source text: On August 7, 2025, the Company’s Board of Directors approved a corporate restructuring to streamline operations, reduce operating expenses, and extend cash runway (the “Restructuring”). In connection with the Restructuring, the Company committed to a reduction in total workforce by approximately 12% (the “RIF”). Affected employees were informed on August 12, 2025. The Company expects the RIF to be completed during the third quarter of 2025, and estimates that it will incur charges of approximately $0.9 million to $1.2 million for severance and other employee termination-related costs during the third quarter of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312525178947/0001193125-25-178947-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.